This article is available online at http://dmd.aspetjournals.org
ABSTRACT:A tyrosinase-directed therapeutic approach for treating malignant melanoma uses depigmenting phenolic prodrugs such as 4-hydroxyanisole (4-HA) for oxidation by melanoma tyrosinase to form cytotoxic o-quinones. However, in a recent clinical trial, both renal and hepatic toxicity were reported as side effects of 4-HA therapy. In the following, 4-HA (200 mg/kg i.p.) administered to mice caused a 7-fold increase in plasma transaminase toxicity, an indication of liver toxicity. Furthermore, 4-HA induced-cytotoxicity toward isolated hepatocytes was preceded by glutathione (GSH) depletion, which was prevented by cytochrome P450 inhibitors that also partly prevented cytotoxicity. The 4-HA metabolite formed by NADPH/microsomes and GSH was identified as a hydroquinone mono-glutathione conjugate. GSH-depleted hepatocytes were much more prone to cytotoxicity induced by 4-HA or its reactive metabolite hydroquinone (HQ). Dicumarol (an NAD(P)H/quinone oxidoreductase inhibitor) also potentiated 4-HA-or HQ-induced toxicity whereas sorbitol, an NADH-generating nutrient, prevented the cytotoxicity. Ethylenediamine (an o-quinone trap) did not prevent 4-HA-induced cytotoxicity, which suggests that the cytotoxicity was not caused by o-quinone as a result of 4-HA ring hydroxylation. Deferoxamine and the antioxidant pyrogallol/4-hydroxy-2,2,6,6-tetramethylpiperidene-1-oxyl (TEMPOL) did not prevent 4-HA-induced cytotoxicity, therefore excluding oxidative stress as a cytotoxic mechanism for 4-HA. A negligible amount of formaldehyde was formed when 4-HA was incubated with rat microsomal/ NADPH. These results suggest that the 4-HA cytotoxic mechanism involves alkylation of cellular proteins by 4-HA epoxide or p-quinone rather than involving oxidative stress.The incidence of malignant melanoma is increasing at an alarming rate among Caucasians (Albino and Fountain, 1993). The lack of effective antimelanoma drugs for treating this form of cancer is partly due to drug resistance (Nathanson and Jilani, 1993). Metastatic melanoma cells are pigmented because active tyrosinase of the melaninsynthesizing pathway is found in melanocytes (Riley, 1991). Thus, the unique ability of melanocytes to produce melanin pigment could be exploited in an enzyme directed melanoma therapy (Jimbow et al., 1993). The selective toxicity of phenolic antimelanoma agents toward local and metastatic melanoma cells could be achieved if the phenolic agent were bioactivated by melanoma tyrosinase to form reactive o-quinones as long as the agent was not bioactivated by hepatic or renal cytochrome P450. Several phenolic agents have been tested for their antimelanoma effect among which 4-hydroxyanisole (4-HA 1 ) had the greatest depigmenting ability. 4-HA was first shown by Riley (1969) to be a melanocytotoxic agent. Depigmentation and tumor shrinkage resulted from both the topical application of 4-HA (Riley, 1969) and intra-arterial infusions of 4-HA into the legs (Morgan, 1984). Unfortunately, 4-HA cl...